RCTs: Peginesatide in patients with anaemia and chronic kidney disease

Source: N Engl J Med Area: News In the New England Journal of Medicine, researchers report the results of four event-driven, randomised, controlled, open-label trials that compared the efficacy and safety of standard erythropoiesis-stimulating agent (ESA) therapy with peginesatide (Omontys), a peptide based ESA approved in the US in March 2012 for the treatment of anaemia caused by chronic kidney disease in adults who are undergoing dialysis.   The EMERALD 1 and EMERALD 2 studies involved patients undergoing haemodialysis. Cardiovascular safety was evaluated by analysis of an adjudicated composite safety end point: death from any cause, stroke, myocardial infarction, or serious adverse events of congestive heart failure, unstable angina, or arrhythmia, with the use of pooled data from the two EMERALD studies and two studies involving patients not undergoing dialysis.   In the EMERALD studies, 1608 patients received peginesatide once monthly or continued to receive epoetin one to three times a ...
Source: NeLM - News - Category: Drugs & Pharmacology Source Type: news